Histologic Ex Vivo Validation of the [ 18 F]SITATE Somatostatin Receptor PET Tracer
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.125.269619 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Nils F Trautwein und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, Germany; nils.trautwein@med.uni-tuebingen.de. Hauptthemen laut MEDLINE: Receptors, Somatostatin, Positron-Emission Tomography, Neuroendocrine Tumors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Radiolabeled somatostatin analogs (SSAs), such as [68Ga]Ga-DOTA SSAs, have transformed imaging and therapeutic strategies. However, their use is constrained by the high cost of generators and their short half-life. In contrast, [18F]SITATE presents a promising alternative, offering the advantage of a longer half-life than 68Ga, along with the cost-effectiveness of cyclotron-based production. This study evaluated the first histologic ex vivo validation of [18F]SITATE.
Methods
This study retrospectively included 47 patients (57% male; mean age, 66.9 ± 14.9 y) with histologically confirmed well-differentiated neuroendocrine neoplasms who underwent [18F]SITATE PET followed by surgery within 4 mo. Lesion uptake was quantified using SUVmean, SUVpeak, SUVmax, and tumor-to-liver ratio (TLR). Histologic somatostatin receptor (SSTR) type 2 expression was determined using histological scores (H-scores), with thresholds defining SSTR scores 1-3. The accuracy of PET imaging for preoperative metastatic detection was evaluated against surgical histology.
Results
PET imaging demonstrated a significant correlation between [18F]SITATE uptake (SUVmean and TLR) and SSTR type 2 H-scores (r = 0.618 and 0.622, respectively; P < 0.0001). SSTR score 3 correlated with increased SUVmean and TLR (P < 0.0001). Among 35 patients with primary resection and lymphadenectomy, PET achieved a sensitivity of 73.9% and specificity of 100%. Conclusion: [18F]SITATE PET imaging strongly correlates with histologic SSTR expression, demonstrating utility in staging and guiding therapeutic decisions in neuroendocrine neoplasms. This 18F-labeled tracer shows specificity comparable to historical [68Ga]Ga-DOTA SSA data, whereas an increase in sensitivity for the detection of locoregional metastases appears possible. Further head-to-head comparisons of [18F]SITATE with traditional [68Ga]Ga-DOTA SSA and histologic validation are warranted to optimize its diagnostic accuracy and clinical impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, Germany; nils.trautwein@med.uni-tuebingen.de.
- ENETS Center of Excellence, University Hospital Tuebingen, Tuebingen, Germany.
- Department of Pathology, University Hospital Tuebingen, Tuebingen, Germany.
- Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany.
- DFG Cluster of Excellence 2180 "Image-Guided and Functional Instructed Tumor Therapy," University of Tuebingen, Tuebingen, Germany.
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard-Karls University Tuebingen, Tuebingen, Germany.
Zitieren
APA
Trautwein, N. F., Mattern, S., Hinterleitner, M., Reischl, G., Schirrmacher, R., Steger, V., Nadalin, S., Nikolaou, K., Schwenck, J., Singer, S., & la Fougère, C. (2025). Histologic Ex Vivo Validation of the [ 18 F]SITATE Somatostatin Receptor PET Tracer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.269619
Vancouver
Trautwein NF, Mattern S, Hinterleitner M, Reischl G, Schirrmacher R, Steger V, et al. Histologic Ex Vivo Validation of the [ 18 F]SITATE Somatostatin Receptor PET Tracer. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.269619
BibTeX
@article{Trautwein2025,
author = {Trautwein, Nils F and Mattern, Sven and Hinterleitner, Martina and Reischl, Gerald and Schirrmacher, Ralf and Steger, Volker and Nadalin, Silvio and Nikolaou, Konstantin and Schwenck, Johannes and Singer, Stephan and la Fougère, Christian},
title = {Histologic Ex Vivo Validation of the [ 18 F]SITATE Somatostatin Receptor PET Tracer},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.125.269619}
}
EUVIMED